Technical Analysis for SBIO - ALPS Medical Breakthroughs ETF
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 34.45 | 1.74% | 0.59 |
SBIO closed up 1.74 percent on Friday, May 3, 2024, on 2.18 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Inside Day | Range Contraction | 1.74% | |
| Gapped Up | Strength | 1.74% | |
| Crossed Above 20 DMA | Bullish | 1.80% | |
| 20 DMA Resistance | Bearish | 5.06% |
| Alert | Time |
|---|---|
| Possible NR7 | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| 2x Volume Pace | 3 days ago |
| 1.5x Volume Pace | 3 days ago |
| 3x Volume Pace | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM.
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
Keywords: Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
Classification
Keywords: Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.8 |
| 52 Week Low | 23.1558 |
| Average Volume | 12,429 |
| 200-Day Moving Average | 30.72 |
| 50-Day Moving Average | 34.67 |
| 20-Day Moving Average | 32.92 |
| 10-Day Moving Average | 32.76 |
| Average True Range | 0.77 |
| RSI (14) | 58.51 |
| ADX | 22.63 |
| +DI | 35.96 |
| -DI | 26.26 |
| Chandelier Exit (Long, 3 ATRs) | 32.52 |
| Chandelier Exit (Short, 3 ATRs) | 33.30 |
| Upper Bollinger Bands | 34.84 |
| Lower Bollinger Band | 30.99 |
| Percent B (%b) | 0.9 |
| BandWidth | 11.71 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.57 |
| MACD Histogram | 0.3255 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.89 | ||||
| Resistance 3 (R3) | 34.88 | 34.74 | 34.81 | ||
| Resistance 2 (R2) | 34.74 | 34.63 | 34.74 | 34.79 | |
| Resistance 1 (R1) | 34.59 | 34.56 | 34.52 | 34.60 | 34.76 |
| Pivot Point | 34.45 | 34.45 | 34.41 | 34.45 | 34.45 |
| Support 1 (S1) | 34.30 | 34.34 | 34.23 | 34.31 | 34.14 |
| Support 2 (S2) | 34.16 | 34.27 | 34.16 | 34.11 | |
| Support 3 (S3) | 34.01 | 34.16 | 34.09 | ||
| Support 4 (S4) | 34.02 |
